LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fenwal, a Fresenius Kabi company, announced today it is has received FDA clearance to include new clinical data in the product label of its platelet additive solution, InterSol™ (PAS 3). A multi-center, non-randomized, open-label retrospective medical chart review study involving about 14,000 transfusions looked at adverse events related to platelet transfusion with and without additive solution. Platelet transfusions using Fenwal InterSol led to a 0.55 percent adverse event reaction rate, while transfusions using only plasma platelets led to a 1.37 percent adverse event reaction rate.
Help employers find you! Check out all the jobs and post your resume.
